Phosphatidylinositol 3-kinase, growth disorders, and cancer
Abstract
Phosphatidylinositol 3-kinase (PI3K) is involved in multiple cell processes, including insulin signaling, cell growth, immunity, and brain development. It is activated in a wide variety of cancers and is being targeted as a treatment, with notable success in lymphoma.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The PI3K pathway is one of the most frequently dysregulated in cancer, and PI3Ks are studied as targets for cancer therapy.
“In addition to their diverse functions established in normal cells, PI3Ks are also quite extensively studied as targets for cancer therapy; the PI3K pathway is one of the most frequently dysregulated in cancer [71,72].”
From Phosphatidylinositol(4,5)bisphosphate: diverse functions at the plasma membrane (2020) · cites this paper as [72]
Aberrant functions of different PLCs and PI3Ks in disease development are well established.
“Although not covered in this review, the importance of aberrant functions of different PLCs and PI3Ks in disease development is well established and continues to expand [11,62,67,72,134–138].”
From Phosphatidylinositol(4,5)bisphosphate: diverse functions at the plasma membrane (2020) · cites this paper as [72]
Alpelisib frequently results in hyperglycemia by inhibiting PI3Kα, which systemically blocks the intracellular action of insulin, resulting in a transient state of insulin resistance and hyperglycemia.
“Alpelisib, a phosphatidylinositol-3-kinase (PI3K) inhibitor, frequently results in hyperglycemia by inhibiting PI3Ka, which systemically blocks the intracellular action of insulin, resulting in a transient state of insulin resistance and hyperglycemia (219).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [219]
Cites
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741 · see citing works
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · see citing works
Self-citationPark, W. S., Do Heo, W., Whalen, J. H., O'Rourke, N. A., Bryan, H. M., Meyer, T., & Teruel, M. N. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.008 · Cited by 167 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740 · see citing works
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0329-9 · Cited by 288 · see citing works
Self-citationPhosphatidylinositol(4,5)bisphosphate: diverse functions at the plasma membrane
Katan, M., & Cockcroft, S. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200041 · Cited by 176 · see citing works
- Authors
- Goncalves, M. D., Hopkins, B. D., & Cantley, L. C.
- Affiliations
- Cornell University (US)
- Weill Cornell Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2052-2062
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2901442091
- Cited by
- 327
- References
- 3
- Citations by year
- 2026: 22 · 2025: 40 · 2024: 47 · 2023: 52 · 2022: 55 · 2021: 40 · 2020: 52 · 2019: 18 · 2017: 1
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- phosphatidylinositol 3-kinase, growth disorders, cancer, insulin signaling, cell growth, immunity, brain development, lymphoma, PI3K inhibitors
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Growth Disorders, Humans, Neoplasms, Oncogenes, Phosphatidylinositols, Signal Transduction, Evolution, Molecular, Cell Proliferation, Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
